These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32950978)

  • 21. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
    Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
    Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
    Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
    Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
    Alsadik S; Yusuf S; Al-Nahhas A
    Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
    Fröss-Baron K; Garske-Roman U; Welin S; Granberg D; Eriksson B; Khan T; Sandström M; Sundin A
    Neuroendocrinology; 2021; 111(4):330-343. PubMed ID: 32097917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.
    Thiis-Evensen E; Poole AC; Nguyen HT; Sponheim J
    BMC Cancer; 2020 May; 20(1):466. PubMed ID: 32448245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
    Herring M; Huynh L; Duh MS; Vekeman F; Tiew A; Neary M; Bergsland E
    Med Oncol; 2017 May; 34(5):88. PubMed ID: 28393314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
    Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT).
    Schiavo Lena M; Partelli S; Castelli P; Andreasi V; Smart CE; Pisa E; Bartolomei M; Bertani E; Zamboni G; Falconi M; Doglioni C
    Endocr Pathol; 2020 Jun; 31(2):119-131. PubMed ID: 32361926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.
    Zacho MD; Iversen P; Villadsen GE; Baunwall SMD; Arveschoug AK; Grønbaek H; Dam G
    Scand J Gastroenterol; 2021 Mar; 56(3):289-297. PubMed ID: 33470864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of
    Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
    World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
    Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequence of therapy and survival in patients with advanced pancreatic neuroendocrine tumours.
    Tsang ES; Loree JM; Speers C; Kennecke HF
    Curr Oncol; 2020 Aug; 27(4):215-219. PubMed ID: 32905342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies.
    Vaghaiwalla T; Ruhle B; Memeh K; Angelos P; Kaplan E; Liao CY; Polite B; Keutgen X
    Surgery; 2021 Jan; 169(1):162-167. PubMed ID: 32446596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.
    Basu S; Ostwal V
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2453-2455. PubMed ID: 27542673
    [No Abstract]   [Full Text] [Related]  

  • 37. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
    Sorbye H; Kong G; Grozinsky-Glasberg S
    Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
    Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
    Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalized
    Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors.
    Yalchin M; Oliveira A; Theocharidou E; Pencharz D; Navalkissoor S; Quigley AM; Walker M; Caplin M; Toumpanakis C
    Clin Nucl Med; 2017 Mar; 42(3):e135-e141. PubMed ID: 27922860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.